Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases

Clin Microbiol Infect. 2004 Aug;10(8):760-2. doi: 10.1111/j.1469-0691.2004.00957.x.

Abstract

An omnibus survey of microbiologists (n = 400) and a survey of participants (n = 49) in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme were conducted to determine the awareness and prevalence of extended-spectrum beta-lactamases (ESBLs), and the regularity and method of screening. Of the omnibus survey participants, 69% screened regularly for ESBLs, compared with 83% of MYSTIC participants. In both surveys, ESBLs were more common in Klebsiella pneumoniae (73% and 79%, respectively) and Escherichia coli (63% and 81%, respectively) than in other bacteria. The surveys demonstrated that awareness of, and testing for, ESBLs is inconsistent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Attitude of Health Personnel*
  • Drug Resistance, Bacterial*
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology
  • Global Health
  • Health Care Surveys*
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / enzymology
  • Meropenem
  • Microbial Sensitivity Tests
  • Physicians*
  • Population Surveillance
  • Thienamycins / pharmacology
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • beta-Lactamases
  • Meropenem